Navigation Links
New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia

patients will stay on their medication."

Key Findings

The first study, Predicting Response to Atypical Antipsychotics Based on Early Response in the Treatment of Schizophrenia, was a post-hoc analysis of data from five randomized, double-blind clinical trials comparing atypical antipsychotic medications in 1,077 patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder, who were at least moderately ill at baseline and were treated for a minimum of two weeks. Patients were assigned into early responder or early non-responder groups at two weeks based on at least a 20 percent improvement on the Positive and Negative Syndrome Scale [PANSS] total score. (PANSS is the primary psychiatric scale used to measure change in schizophrenia symptoms.) Subsequent response at endpoint was defined as at least a 20 percent improvement in PANSS total score (mild improvement), or at least a 40 percent improvement in PANSS total score (moderate improvement). The following was determined at the three-month endpoint:

      - Seventy-four percent of patients identified as early responders or

        early non-responders maintained their status.

      - Early responders showed significantly greater improvements in symptoms

        at all time points compared to early non-responders.

      - Early non-response appears to be an accurate predictor of subsequent

        non-response to antipsychotic medications.

Researchers for the second study, Clinical, Functional, and Economic Ramifications of Early Non-Response to Antipsychotics in the Naturalistic Treatment of Schizophrenia, performed a post-hoc analysis on data from a one- year, multi-site, randomized open-label study of antipsychotic medications. Patients who completed eight weeks of treatment on their initial medication (n=443) were included in the analysis. Patients with early response were identified as having at least 20 percent improvement from study start - baselin
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
4. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
5. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
6. Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data
7. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
8. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
9. Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron
10. Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability
11. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
Post Your Comments:
(Date:7/29/2014)... , July 29, 2014 Research ... "Global Respiratory Devices Market 2014-2018" report to ... A respiratory device is a medical device ... is having difficulty in breathing and cannot achieve adequate ... such as cystic fibrosis, asthma, COPD, and ARDS require ...
(Date:7/29/2014)... Ill. , July 29, 2014  Sysmex America, ... and information systems technology, will feature an exhibit booth ... Annual Meeting and Clinical Lab Expo in ... 2014. "We are extremely excited to ... opportunity to interact with our customers and continue the ...
(Date:7/29/2014)... Calif. , July 29, 2014  Based ... response systems (PERS) market, Frost & Sullivan recognizes ... Sullivan Award for Price Performance Value Leadership. MobileHelp,s ... directly captures expectations for tech progression in personal ... consumers for these solutions. MobileHelp is ...
Breaking Medicine Technology:Global Respiratory Devices Market 2014-2018 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... America, Inc. (SAI), a leading medical diagnostic instrument ... Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: ... for Sysmex America, Inc. to provide fully automated ... of the systems has been completed.   ...
... Medical Systems (NYSE: VAR ) will hold an ... of  the American Society for Therapeutic Radiology and Oncology (ASTRO) ... are invited to join senior management for a review of ... at ASTRO. Varian will host a meeting with ...
Cached Medicine Technology:Sysmex America Announces LabCorp Hematology Automation Agreement 2Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010 2
(Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
(Date:7/29/2014)... 29, 2014 “Our years of ... homeowners fail to insulate their homes properly simply ... of preventing heat transfer and conduction,” Clean Crawls ... they’ve recently released an article explaining exactly how ... their energy bills. , To contact Clean Crawls ...
(Date:7/29/2014)... “Approximately 18% of our population suffers from allergies, ... Western Washington Medical Group says in their recently ... from allergies to seek medical attention. , “Billions of ... in the United States,” they continue. “Many people have ... themselves, rather than seeking the appropriate treatment.” , Fortunately, ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign ... absorb embarrassing odors in the office. PoofPad is a discrete ... a desk drawer. This compact packaging is designed for ease ... on the pad and poof away! , “We’ve all been ... someone appears out of nowhere. It’s embarrassing and unpleasant for ...
(Date:7/29/2014)... 29, 2014 Riverdale Urgent Care is ... do. Through their presence at local events, partnerships and ... more than just a medical service for the Riverdale ... money in support of Riverdale RiverFest and South Riverdale ... that features local musicians and entertainers, arts and crafts, ...
Breaking Medicine News(10 mins):Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 3
... Regions Hospital,this week opens a new 16-bed inpatient ... the region -- with an innovative way of caring ... schedule,providing improved continuity and a better experience for patients., ... provide care for,patients once they arrive in the emergency ...
... Late-Stage and Marketed ... ... England, February 18 /PRNewswire/,-- EUSA Pharma Inc (,EUSA,), a transatlantic ... today,announced that it has out-licensed the exclusive world-wide rights to ...
... Cancer Society study of twelve types of cancer among ... were significantly more likely to present with advanced stage ... which appears in the March issue of The Lancet ... investigate insurance status and stage of diagnosis for a ...
... known to impair the cognitive health of people, but ... learning and memory problems. A new National Institutes ... increased levels of a stress hormone produced by the ... the region of the brain responsible for learning and ...
... District Hospital, Dar es Salaam, Tanzania, WASHINGTON, Feb. ... President, First Lady, my dear wife -- Mr.,President, welcome again ... you so much, again, for PEPFAR, the President,s,Emergency Plan for ... -- these two buildings, a,facility we just visited, and again, ...
... Wing, professor of psychiatry and human behavior at The Warren ... Weight Control & Diabetes Research Center at The Miriam Hospital, ... dieters who lose weight and keep the pounds off, have ... , Using new research findings, Wing will make her case ...
Cached Medicine News:Health News:Regions Hospital to Open New Inpatient Behavioral Health Unit 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 3Health News:Major study links insurance status to advanced stage in multiple cancers 2Health News:Stress hormone impacts memory, learning in diabetic rodents 2Health News:Remarks By President Bush and President Kikwete of Tanzania at Roundtable on Pepfar 2Health News:Large changes needed to address global obesity epidemic 2
100L...
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: